Immunotherapy’s Role in TNBC May Be in Combination – OncLive
OncLive |
Immunotherapy's Role in TNBC May Be in Combination
OncLive Soliman adds that ongoing work is combining immunotherapy with other biologics. The subsets of TNBC that are very susceptible to DNA-damaging agents may also respond to immunotherapy. Additionally, PARP inhibitors may be combined with other sensitizing … |
